COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)					9 Months Ended
	Jul. 22, 2021	Jul. 14, 2021	Jan. 21, 2021	Jan. 10, 2020	Sep. 30, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Reverse Stock Split Description			The letter demands that the Company (i) deem ineffective the December 30, 2020 amendment to our Amended and Restated Certificate of Incorporation in which the Company effected a one-for-four reverse stock split of its common stock due to the manner in which non-votes by brokers were tabulated, (ii) seek appropriate relief for damages allegedly suffered by the company and its stockholders or seek a valid stockholder approval of the amendment and reverse stock split, and (iii) adopt adequate internal controls to prevent a recurrence of the alleged misconduct. The Company disputes that the amendment was ineffective or that there were any inadequate internal controls related to the same. However, to eliminate any questions about the amendment, the Company ratified the amendment at a special stockholders’ meeting pursuant to Section 204 of the Delaware General Corporation Law.
Payment for stockholder changes	$ 60,000	$ 30,000	$ 65,000
License agreement description					Jay Pharma, Tikkun Olam LLC (“TO LLC”) and Tikkun Olam Hemp LLC (“TOH”) entered into a license agreement dated on January 10, 2020, pursuant to which Jay Pharma would acquire certain in-licensed and owned intellectual property rights related to the cannabis products in the United States (presently excluding the state of New York) from TO LLC and TOH, each of which is an affiliate of TO Holdings, in exchange for royalty payments of (i) four percent (4.0%) of net sales of OTC cancer products made via consumer channels; (ii) five percent (5.0%) of net sales of beauty products made via consumer channels; and (iii) three percent (3.0%) of net sales of OTC cancer products made via professional channels, along with a minimum net royalty payment starting in January 1, 2022 and progressively increasing up to a cap of $400,000 maximum each year for the first 10 years, then $600,000 maximum each year for the next 5 years, and an annual maximum cap of $750,000 each year thereafter during the term of the agreement.
Top And Tikkun [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Assignment and assumption agreements description				TOP and Tikkun regarding all of Tikkun’s (i) in-licensed rights and obligations to commercialize pharmaceutical products related to GVHD under the relevant Sublicense in the U.S. and (ii) certain skincare business and all of Tikkun’s rights related thereto as of the January 10, 2020 effective date. Jay Pharma agreed to issue 8,288,006 common shares of Jay Pharma to Tikkun in exchange for these rights
T O C I And Tikkun [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Assignment and assumption agreements description				TOCI and Tikkun regarding all of Tikkun’s in-licensed rights and obligations to commercialize pharmaceutical products related to GVHD under the relevant sublicense anywhere in the world outside the U.S. Jay Pharma agreed to issue 2,072,001 common shares of Jay Pharma to Tikkun in exchange for these rights.
Vogal Nathan Purchase Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalties percentage					2.00%
Payments for Royalties					$ 20,000,000
Vogal Nathan Purchase Agreement [Member] | One Time Milestone [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Commitment, Amount					200,000
Vogal Nathan Purchase Agreement [Member] | Additional Milestone [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Commitment, Amount					$ 300,000